Analyst fair value estimates for APi Group have shifted higher, with the updated price target moving from US$44.90 to US$51.36 per share. This change sits alongside a cluster of refreshed research ...
KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results